Viral Vector and Plasmid DNA Testing Services Market to Surpass US$ 565.3 Million by 2027 - Coherent Market Insights

Global Viral Vector and Plasmid DNA Testing Services Market, by Testing Services (Safety, Genetic Characterization, Purity, Identity, and Potency), by End User (Research Organizations and Pharmaceutical and Biotechnological Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 76.4 million in 2018 and is expected to exhibit a CAGR of 25.0% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing focus of market players on developing innovative techniques in order enhance the characterization of viral vectors are expected to drive growth of the viral vector and plasmid DNA testing services market over the forecast period. For instance, Promega Corporation developed Vac-Man 96 Vacuum Manifold, which supports processing of SV 96 plates for plasmid, genomic, and PCR product purification. The product is used with Wizard SV 96 Plasmid DNA Purification System for isolation of plasmid DNA. Moreover, in September 2019, BIA Separations launched CORNERSTONE AAV Process Development Service. With this launch the company introduced CIMasphere, a purification technology that enables removal of host cell protein and host cell DNA before manufacturing, in order to deliver pure AAV products.

Major players are focused on collaborations and acquisitions, which is expected to propel the market growth over the forecast period. For instance, in November 2019, Lonza entered into a gene therapy collaboration with DiNAQOR AG. Under the collaboration, Lonza will provide preclinical, clinical, and commercialization support for DiNAQOR’s preclinical program DiNA-001, a gene therapy program. Moreover, in October 2018, Eurofins Scientific acquired EnvironeX Group Inc., a Canada-based provider of testing services in the pharmaceutical, AgriFood, and environment sectors.

Browse 26 Market Data Tables and 22 Figures spread through 145 pages and in-depth TOC on ‘Viral Vector and Plasmid DNA Testing Services Market’- global forecast to 2027, by Testing Services (Safety, Genetic Characterization, Purity, Identity, and Potency), by End User (Research Organizations, Pharmaceutical, and Biotechnological Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)'

To know the latest trends and insights prevalent in the Viral Vector and Plasmid DNA Testing Services Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/viral-vector-and-plasmid-dna-testing-services-market-3637

North America is expected to hold a dominant position in the viral vector and plasmid DNA testing services market, owing to adoption of inorganic growth strategies such as mergers, partnerships, and acquisitions by market players, in order to expand their product portfolio and strengthen their market presence, which in turn are expected to fuel growth of the regional market over the forecast period. For instance, in February 2019, Charles River Laboratories, Inc. acquired Citoxlab, a non-clinical CRO that offers regulated safety assessment services, non-regulated discovery services, and medical device testing services for around US$ 510 million. The acquisition resulted in expansion of Charles River’s global presence as a leading contract research organization (CRO) and enhanced its offerings in the market.

Furthermore, in September 2016, Charles River Laboratories, Inc. and PathoQuest entered into a partnership, in order to offer improved viral safety service to biopharmaceutical companies.

Key Takeaways of the Viral Vector and Plasmid DNA Testing Services Market:

• The global viral vector and plasmid DNA testing services market is expected to exhibit a CAGR of 25.0% over the forecast period, owing to rising business expansion by inaugurating facility centers, merger and acquisitions, product launches, and others by market players. For instance, in May 2016, Merck KGaA announced capacity expansion of operations at its Carlsbad, California facility, in order to offer cell and gene therapy services. The facility also supports development of products from clinical to commercial scales.
• Among testing services, safety segment held a dominant position in the viral vector and plasmid DNA testing services market in 2018, owing to increasing product or service launches by the manufacturers, which is expected to propel the market growth. For instance, in September 2018, Merck KGaA launched GMP BioReliance biosafety testing laboratory in Singapore to expand its clinical testing services in the Asia Pacific market. Moreover, in January 2020, LabCorp launched a suite of cell and gene therapy development solutions from its drug development business of Covance. The solution is developed to accelerate the development of cell and gene therapy. Under this, Labcorp offers preclinical solutions and clinical solutions such as bioanalysis testing and services, and safety assessment.
• Companies operating in the global viral vector and plasmid DNA testing services market include Charles River Laboratories, Inc., WuXi AppTec Co., Ltd., Cobra Biologics and Pharmaceutical Services, Merck KGaA, Lonza, Eurofins Scientific, FinVector Vision Therapies, Advanced Bioscience Laboratories, Inc., Takara Bio Inc., ViruSure GmbH, and Genezen Laboratories